Incyte
INCY
Market cap $13.9B

71.93 USD

-0.54

0.75%

At close Jan 17, 4:00 PM EST

After hours

72.28

+0.35

0.49%

1 day

-0.75%

5 days

1.97%

1 month

3.65%

3 months

8.28%

6 months

10.15%

Year to date

3.45%

1 year

17.00%

5 years

-10.65%

10 years

-7.07%

About: Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.

Employees: 2,524

Industrials Commercial Physical & Biological Research

0

Funds holding %

of 6,823 funds

0

Analysts bullish %

of 10 analysts

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

40% more funds holding in top 10

Funds holding in top 10: 5 [Q2] → 7 (+2) [Q3]

16% more call options, than puts

Call options by funds: $49.9M | Put options by funds: $43M

16% more first-time investments, than exits

New positions opened: 81 | Existing positions closed: 70

5.76% more ownership

Funds ownership: 89.06% [Q2] → 94.82% (+5.76%) [Q3]

1% more funds holding

Funds holding: 569 [Q2] → 572 (+3) [Q3]

1% less capital invested

Capital invested by funds: $12.1B [Q2] → $12B (-$170M) [Q3]

35% less repeat investments, than reductions

Existing positions increased: 166 | Existing positions reduced: 255

See Fund Rankings

Research analyst outlook

10 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$52

28%

downside

Avg. target

$75

5%

upside

High target

$97

35%

upside

10 analyst ratings

3 positive

30%

6 neutral

60%

1 negative

10%

Wells Fargo Derek Archila 44% 1-year accuracy 16 / 36 met price target	3%downside $70	Equal-Weight Maintained	19 Dec 2024
UBS Nicholas Holowko 50% 1-year accuracy 4 / 8 met price target	7%upside $77	Neutral Assumed	17 Dec 2024
RBC Capital Brian Abrahams 13% 1-year accuracy 10 / 79 met price target	3%upside $74	Sector Perform Maintained	19 Nov 2024
Citigroup David Lebowitz 50% 1-year accuracy 11 / 22 met price target	35%upside $97	Buy Maintained	30 Oct 2024
Morgan Stanley Vikram Purohit 17% 1-year accuracy 1 / 6 met price target	4%downside $69	Equal-Weight Maintained	30 Oct 2024

See Analyst Rankings

Financial journalist opinion

Based on 11 articles about INCY published over the past 30 days

Zacks Investment Research

Incyte Gains 15.3% in a Year: Is There Room for Further Growth?

INCY has delivered a good performance in the past year on positive data readouts and encouraging pipeline progress. We believe there is room for further growth at current levels.

Incyte Gains 15.3% in a Year: Is There Room for Further Growth?

Incyte and Syndax Announce U.S. Food and Drug Administration (FDA) Approval of Niktimvo™ (axatilimab-csfr) 9 mg and 22 mg Vial Sizes

– U.S. launch expected in early February – – Niktimvo is the first and only approved treatment for chronic GVHD that targets CSF-1R to reduce the drivers of inflammation and fibrosis – – Pivotal data from the AGAVE-201 trial supporting FDA approval show treatment with Niktimvo resulted in durable responses across all organs studied and patient subgroups – WILMINGTON, Del. and WALTHAM, Mass.

Incyte and Syndax Announce U.S. Food and Drug Administration (FDA) Approval of Niktimvo™ (axatilimab-csfr) 9 mg and 22 mg Vial Sizes

Zacks Investment Research

5 Biotech Stocks Worth Adding to Your Portfolio in 2025

New drug approvals and pipeline progress are likely to help maintain the momentum for the Zacks Biomedical and Genetics industry despite the uncertain macro environment. A strong portfolio and solid pipeline progress position INCY, BMRN, EXEL, HALO and BPMC well in this volatile sector.

5 Biotech Stocks Worth Adding to Your Portfolio in 2025

Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025

This article will provide an in-depth analysis of drugs being developed to combat cancer. Big Pharma is keenly interested in the global cancer therapeutics market, which is expected to exceed $400 billion by 2028. Every year, the FDA and EMA approve dozens of anticancer drugs, so Seeking Alpha readers should be careful when making decisions.

Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025

Zacks Investment Research

Has Incyte (INCY) Outpaced Other Medical Stocks This Year?

Here is how Incyte (INCY) and Atara Biotherapeutics (ATRA) have performed compared to their sector so far this year.

Has Incyte (INCY) Outpaced Other Medical Stocks This Year?

Incyte Highlights Commercial Growth, Clinical Progress and 2025 Milestones at the 43rd Annual J.P. Morgan Healthcare Conference

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Highlights Commercial Growth, Clinical Progress and 2025 Milestones at the 43rd Annual J.P. Morgan Healthcare Conference.

Incyte Highlights Commercial Growth, Clinical Progress and 2025 Milestones at the 43rd Annual J.P. Morgan Healthcare Conference

Incyte: Multiple Drug Launches Bode Well For Future Growth

Incyte's robust growth, led by JAKAFI and OPZELURA, is set to increase with new product launches of MONJUVI, ZYNZY, and NIKTIMVO in 2025. Analysts expect Incyte's revenues to grow by ~10% annually until JAKAFI's patent expiration in 2028, however, recent sales growth momentum and new product launches seem poised to outperform expectations. The company aims to launch 10 high-impact products by 2030, with promising pipeline assets like INCB123667 and povorcitinib showing promising clinical activity.

Incyte: Multiple Drug Launches Bode Well For Future Growth

Zacks Investment Research

INCY vs. VRTX: Which Stock Is the Better Value Option?

Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Incyte (INCY) and Vertex Pharmaceuticals (VRTX). But which of these two stocks presents investors with the better value opportunity right now?

INCY vs. VRTX: Which Stock Is the Better Value Option?

Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).

Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).

Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

See News Rankings

Charts implemented using Lightweight Charts™